Skip to search formSkip to main contentSkip to account menu

XL281

Known as: RAF Kinase Inhibitor XL281 
An orally active, small molecule with potential antineoplastic activity. XL281 specifically inhibits RAF kinases, located downstream from RAS in the… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Mutant B-Raf Kinase Inhibitors as Anticancer Agents.
The Ras/Raf/MEK/ERK signaling pathway involves various kinases in which each kinase is associated with one another through… 
2015
2015
Clinico‐morphological features of BRAF inhibition–induced proliferative skin lesions in cancer patients
The use of BRAF inhibitors may lead to the development of cutaneous toxicities such as rashes, photosensitivity, alopecia… 
2015
2015
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors
SummaryBackground XL281 is a potent and selective inhibitor of wild-type and mutant RAF kinases with anti-tumor activity in… 
Review
2013
Review
2013
B-Raf and the inhibitors: from bench to bedside
The B-Raf protein is a key signaling molecule in the mitogen activated protein kinase (MAPK) signaling pathway and has been… 
2010
2010
PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial.
8592 Background: Tumor regressions have been observed in a significant proportion of advanced melanoma patients treated with… 
Review
2010
Review
2010
Anticipating drug resistance in the MAP kinase pathway
Kinases have become one of the most important families of drug targets for many diseases and for cancer in particular (Zhang et… 
Highly Cited
2009
Highly Cited
2009
A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors.
3513 Background: XL281 is a potent and selective inhibitor of wild type and mutant RAF kinases showing anti-tumor activity in… 
2009
2009
Market watch: Sales from licensed and acquired products to increase by 2013
AVos Life sciences has analysed the revenue contribution of organically developed, licensed or co-developed, acquired and joint… 
2009
2009
Deal watch: Bristol–Myers Squibb and Exelixis collaborate on kinase inhibitors
2008
2008
383 POSTER A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients (pts) with advanced solid tumors
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)